Cleveland Clinic Adopts 4DMedical's AI Imaging: What It Means for ASX Healthcare Stocks

Cleveland Clinic, one of America's most prestigious hospitals, has adopted 4DMedical's (ASX:4DX) CT: VQ imaging technology. This marks the third major US academic medical centre to deploy the technology in just over three months since receiving FDA clearance.

The rapid adoption by Stanford University, University of Miami, and now the Cleveland Clinic signals growing confidence in AI-driven medical imaging solutions. For investors tracking ASX healthcare stocks, this highlights how Australian medtech companies are gaining traction in the world's largest healthcare market.

AI Medical Imaging: A Fast-Growing Market

The global AI in medical imaging market was valued at approximately US$1.6 billion in 2024 and is projected to grow at roughly 27% annually through 2034. Several factors are driving this expansion.

Hospitals face mounting pressure from rising imaging volumes and a growing shortage of radiologists, forecast to reach nearly 20,000 in the US by 2034. AI tools that streamline workflows and improve diagnostic speed are becoming essential rather than optional.

Software-based diagnostic solutions offer clear advantages: they integrate with existing infrastructure, require no new hardware, and operate on a recurring revenue model. CT imaging leads the market, accounting for about 37% of the segment, while respiratory diagnostics represent one of the fastest-growing categories as hospitals seek non-invasive alternatives.

North America dominates the market with over 40% share, driven by high healthcare expenditure, strong regulatory frameworks, and early technology adoption, creating a favourable environment for companies with FDA-cleared products.

‍

Why Academic Medical Centre Adoption Matters

When tier-one hospitals adopt new technology, it sends a powerful signal to the broader healthcare system. Cleveland Clinic, named to the US News Honor Roll for 35 consecutive years, is precisely the kind of institution that influences purchasing decisions at community hospitals and regional health networks.

The Cleveland Clinic agreement includes a one-month introductory pricing period to integrate CT: VQ into clinical workflows, followed by full commercial terms. This "land and expand" model allows hospitals to validate the technology before committing to ongoing subscriptions. Academic centres also serve as reference sites that can accelerate broader market adoption.

4DMedical: A Case Study in Commercial Traction

4DMedical's CT: VQ technology received FDA 510(k) clearance and immediate CMS (Medicare) reimbursement in early September 2025. The technology addresses a US$1.1 billion addressable market, with over one million nuclear VQ scans performed annually in the US.

The company operates on a software-as-a-service model, delivering its technology through existing hospital CT infrastructure without additional equipment.

Several developments have strengthened the company's commercial position. Pro Medicus (ASX: PME), a highly regarded medical imaging software company, made an A$10 million strategic investment in July 2025, seen as a vote of confidence from an established industry leader.

In December 2025, Philips announced a distribution partnership covering North America, with a minimum US$10 million commitment over two years. The same week, Health Canada granted regulatory approval, enabling immediate commercial deployment across Canada.

4DMedical's market capitalisation has crossed the A$1.5 billion threshold. Shares have risen from lows around 24 cents in mid-2025, trading above A$3.40 following the Cleveland Clinic announcement.

Valuation considerations: While the commercial pathway looks increasingly credible, the company is still scaling revenue and operating at a loss. FY2025 operating revenue was A$5.9 million, up 56% year-on-year. Investors will need to weigh strong momentum against execution risk.

Key Takeaways for Investors

• AI adoption in US healthcare is accelerating. The structural shortage of radiologists and rising imaging volumes create sustained demand for software-based diagnostic tools. Australian medtech companies with FDA-cleared products are well-positioned for this multi-year trend.
  
  
• Academic hospital validation de-risks the commercial pathway. Three-tier-one US institutions adopting CT: VQ within three months provides meaningful clinical validation. These reference sites can influence purchasing decisions across broader hospital networks.
  
  
• The SaaS model supports recurring revenue. Software-as-a-service delivery means ongoing subscription income rather than one-off sales, attractive for investors seeking predictable cash flows as adoption scales.
  
  
• Execution remains the key variable. Early wins are encouraging, but converting pilot programs into sustained recurring revenue will determine whether the current valuation is justified. FY2026 will be a critical year for demonstrating commercial traction.
  
  

Track momentum in ASX healthcare stocks using ASR's HALO platform, or explore growth opportunities through the Investing Report.

‍